Skip to main content
Premium Trial:

Request an Annual Quote

Genome Therapeutics Raises $9M in Common Stock Placement

NEW YORK, Sept. 30 (GenomeWeb News) - Genome Therapeutics has raised approximately $9 million in net proceeds after expenses ($9.55 million total) through a private placement of common stock, the company said today.

Approximately 3.8 million new shares of Genome Therapeutics common stock were issued to several new institutional shareholders, led by Domain Public Equity Partners. Investors also received warrants to purchase 1.9 million shares at an exercise price of $3.48 per share. The warrants are exercisable for a period of five years.

According to Steven Rauscher, CEO of Genome Therapeutics, the company will use the additional financing to support clinical studies of its lead product candidate, Ramoplanin, currently in clinical development for the prevention, treatment, and control of hospital-based infections.

The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.